Rizatriptan reduces vestibular-induced motion sickness in migraineurs

The Journal of Headache and Pain

Original

Dawn A. Marcus¹  Joseph M. Furman²  Carey D. Balaban² 

[1] Department of Anesthesiology, University of Pittsburgh School of Medicine, Pain Medicine, Centre Commons Building, Suite 400, 5750 Centre Avenue, 15206, Pittsburgh, PA, USA;Department of Otolaryngology, Eye and Ear Institute, University of Pittsburgh School of Medicine, 203 Lothrop Street, 15213, Pittsburgh, PA, USA;

关键词: Migraine;    Motion sickness;    Triptans;   

DOI  :  10.1007/s10194-010-0250-z

 received in 2010-05-20, accepted in 2010-08-12,  发布年份 2010

来源: Springer

【 摘 要 】

A previous pilot study suggested that rizatriptan reduces motion sickness induced by complex vestibular stimulation. In this double-blind, randomized, placebo-controlled study we measured motion sickness in response to a complex vestibular stimulus following pretreatment with either rizatriptan or a placebo. Subjects included 25 migraineurs with or without migraine-related dizziness (23 females) aged 21–45 years (31.0 ± 7.8 years). Motion sickness was induced by off-vertical axis rotation in darkness, which stimulates both the semicircular canals and otolith organs of the vestibular apparatus. Results indicated that of the 15 subjects who experienced vestibular-induced motion sickness when pretreated with placebo, 13 showed a decrease in motion sickness following pretreatment with rizatriptan as compared to pretreatment with placebo (P < 0.02). This significant effect was not seen when subjects were exposed to more provocative vestibular stimulation. We conclude that the serotonin agonist, rizatriptan, reduces vestibular-induced motion sickness by influencing serotonergic vestibular-autonomic projections.

【 授权许可】

Unknown   
© Springer-Verlag 2010